Urohealth Systems will take over Imagyn Medical in a stock deal which values Imagyn at about $70 million. The deal will add micro-invasive systems to diagnose and treat gynaecological and reproductive disorders to Urohealth's products in urology and general surgery.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?